CN105403709A - Whole-blood one-step alpha fetoprotein collaurum detection kit and detection method thereof - Google Patents
Whole-blood one-step alpha fetoprotein collaurum detection kit and detection method thereof Download PDFInfo
- Publication number
- CN105403709A CN105403709A CN201510708316.0A CN201510708316A CN105403709A CN 105403709 A CN105403709 A CN 105403709A CN 201510708316 A CN201510708316 A CN 201510708316A CN 105403709 A CN105403709 A CN 105403709A
- Authority
- CN
- China
- Prior art keywords
- line
- collaurum
- fetoprotein
- alpha
- blood
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 238000001514 detection method Methods 0.000 title claims abstract description 33
- 239000008280 blood Substances 0.000 title claims abstract description 19
- 102000013529 alpha-Fetoproteins Human genes 0.000 title abstract description 40
- 108010026331 alpha-Fetoproteins Proteins 0.000 claims abstract description 44
- 239000003153 chemical reaction reagent Substances 0.000 claims abstract description 32
- 229920001220 nitrocellulos Polymers 0.000 claims abstract description 18
- 239000003365 glass fiber Substances 0.000 claims abstract description 9
- 239000004033 plastic Substances 0.000 claims abstract description 7
- 229920003023 plastic Polymers 0.000 claims abstract description 7
- 241000283973 Oryctolagus cuniculus Species 0.000 claims abstract description 5
- 210000004369 blood Anatomy 0.000 claims description 16
- 239000000020 Nitrocellulose Substances 0.000 claims description 14
- 239000000084 colloidal system Substances 0.000 claims description 11
- 239000012528 membrane Substances 0.000 claims description 11
- 238000000034 method Methods 0.000 claims description 8
- 238000012856 packing Methods 0.000 claims description 6
- 238000003556 assay Methods 0.000 claims description 5
- 101100074336 Xenopus laevis ripply2.1 gene Proteins 0.000 claims description 4
- 230000002159 abnormal effect Effects 0.000 claims description 4
- 238000012360 testing method Methods 0.000 claims description 4
- 239000005030 aluminium foil Substances 0.000 claims description 3
- 241000283707 Capra Species 0.000 claims description 2
- 241000218202 Coptis Species 0.000 claims description 2
- 235000002991 Coptis groenlandica Nutrition 0.000 claims description 2
- 230000001681 protective effect Effects 0.000 claims description 2
- 102100023635 Alpha-fetoprotein Human genes 0.000 claims 9
- 230000009286 beneficial effect Effects 0.000 abstract description 2
- 201000010099 disease Diseases 0.000 abstract description 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract description 2
- 238000005070 sampling Methods 0.000 abstract 3
- 102000004641 Fetal Proteins Human genes 0.000 abstract 1
- 108010003471 Fetal Proteins Proteins 0.000 abstract 1
- 238000010241 blood sampling Methods 0.000 abstract 1
- 239000002985 plastic film Substances 0.000 abstract 1
- 229920006255 plastic film Polymers 0.000 abstract 1
- 210000003754 fetus Anatomy 0.000 description 3
- 210000005229 liver cell Anatomy 0.000 description 3
- 238000010586 diagram Methods 0.000 description 2
- 230000006872 improvement Effects 0.000 description 2
- 108090000623 proteins and genes Proteins 0.000 description 2
- 102000004169 proteins and genes Human genes 0.000 description 2
- 210000002966 serum Anatomy 0.000 description 2
- 102000004506 Blood Proteins Human genes 0.000 description 1
- 108010017384 Blood Proteins Proteins 0.000 description 1
- 206010008909 Chronic Hepatitis Diseases 0.000 description 1
- 208000032170 Congenital Abnormalities Diseases 0.000 description 1
- 102000003886 Glycoproteins Human genes 0.000 description 1
- 108090000288 Glycoproteins Proteins 0.000 description 1
- 206010019755 Hepatitis chronic active Diseases 0.000 description 1
- 206010028980 Neoplasm Diseases 0.000 description 1
- 201000009928 Patau syndrome Diseases 0.000 description 1
- 201000010829 Spina bifida Diseases 0.000 description 1
- 208000006097 Spinal Dysraphism Diseases 0.000 description 1
- 206010043276 Teratoma Diseases 0.000 description 1
- 206010044686 Trisomy 13 Diseases 0.000 description 1
- 208000006284 Trisomy 13 Syndrome Diseases 0.000 description 1
- 241000700605 Viruses Species 0.000 description 1
- 101150055123 afp gene Proteins 0.000 description 1
- 206010002320 anencephaly Diseases 0.000 description 1
- 230000008901 benefit Effects 0.000 description 1
- 201000000053 blastoma Diseases 0.000 description 1
- 201000011510 cancer Diseases 0.000 description 1
- 150000001720 carbohydrates Chemical class 0.000 description 1
- 235000014633 carbohydrates Nutrition 0.000 description 1
- 230000008859 change Effects 0.000 description 1
- 208000019425 cirrhosis of liver Diseases 0.000 description 1
- 230000007423 decrease Effects 0.000 description 1
- 230000007547 defect Effects 0.000 description 1
- 238000003745 diagnosis Methods 0.000 description 1
- 230000000694 effects Effects 0.000 description 1
- 201000008184 embryoma Diseases 0.000 description 1
- 230000001605 fetal effect Effects 0.000 description 1
- PCHJSUWPFVWCPO-UHFFFAOYSA-N gold Chemical compound [Au] PCHJSUWPFVWCPO-UHFFFAOYSA-N 0.000 description 1
- 239000010931 gold Substances 0.000 description 1
- 229910052737 gold Inorganic materials 0.000 description 1
- 208000006454 hepatitis Diseases 0.000 description 1
- 231100000283 hepatitis Toxicity 0.000 description 1
- 206010020718 hyperplasia Diseases 0.000 description 1
- 210000004185 liver Anatomy 0.000 description 1
- 201000007270 liver cancer Diseases 0.000 description 1
- 238000011068 loading method Methods 0.000 description 1
- 210000001161 mammalian embryo Anatomy 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 201000010193 neural tube defect Diseases 0.000 description 1
- 230000035935 pregnancy Effects 0.000 description 1
- 230000008569 process Effects 0.000 description 1
- 230000008439 repair process Effects 0.000 description 1
Classifications
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
- G01N33/6893—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
- G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
- G01N2333/46—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans from vertebrates
- G01N2333/47—Assays involving proteins of known structure or function as defined in the subgroups
- G01N2333/4701—Details
- G01N2333/471—Pregnancy proteins, e.g. placenta proteins, alpha-feto-protein, pregnancy specific beta glycoprotein
Landscapes
- Life Sciences & Earth Sciences (AREA)
- Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Molecular Biology (AREA)
- Chemical & Material Sciences (AREA)
- Biomedical Technology (AREA)
- Urology & Nephrology (AREA)
- Hematology (AREA)
- Immunology (AREA)
- Biotechnology (AREA)
- Microbiology (AREA)
- Cell Biology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Food Science & Technology (AREA)
- Medicinal Chemistry (AREA)
- Physics & Mathematics (AREA)
- Analytical Chemistry (AREA)
- Biochemistry (AREA)
- General Health & Medical Sciences (AREA)
- General Physics & Mathematics (AREA)
- Pathology (AREA)
- Investigating Or Analysing Biological Materials (AREA)
Abstract
The invention provides a whole-blood one-step alpha fetoprotein collaurum detection kit which comprises a box base, a box cover and a reagent strip, wherein the reagent strip is fixed between the box base and the box cover; an observation port is formed on the box cover; a sampling hole is formed on the side between the box cover and the box base; the sampling hole can be directly applied to the fingertip blood-sampling or the sampling detection; the reagent strip is divided into an upper layer and a bottom layer; a plastic film is arranged on the bottom layer; a glass fiber film, a first nitrocellulose film, a plastic protecting film and a second nitrocellulose film are successively arrayed end-to-end on the upper layer; a rabbit IgG collaurum is arranged on the glass fiber film; the first nitrocellulose film serves as a bridging film with alpha fetoprotein collaurum; an anti-alpha fetoprotein collaurum monoclonal antibody and a goat-anti-rabbit IgG are arranged on the second nitrocellulose film. Compared with the prior art, the whole-blood one-step alpha fetoprotein collaurum detection kit has the beneficial effects that the alpha fetoprotein (AFP) content and concentration in a human body can be quickly and accurately detected and the diseases can be timely diagnosed.
Description
Technical field
The present invention relates to invention immune colloid gold detection kit, particularly relate to whole blood single stage method alpha-fetoprotein gold-immunochromatographyreagent reagent for assay box and detection method.
Background technology
Alpha-fetoprotein (AFP) is a kind of single chain glycoprotein, and be a kind of Embryo associated protein, molecular weight is about 69kDa, is made up of the carbohydrates of 96% protein and 4%.AFP mainly synthesizes in fetus liver, accounts for 1/3 of plasma proteins total amount at fetus 13 weeks AFP.Reached top at pregnant 30 weeks, decline gradually later, during birth, Plasma is about 1% of peak period, about 40mg/L.After fetal birth about two weeks, alpha-fetoprotein disappears from blood, therefore in normal human serum the content of alpha-fetoprotein still less than 20ng/mL.
As everyone knows, alpha-fetoprotein (AFP) has the value of diagnosing primary liver cancer.But a large amount of clinical manifestation proves, part patient with liver cirrhosis there will be AFP rise phenomenon, but does not all occur cancer sign for many years.And in oxyhepatitis, chronic active hepatitis crowd, the AFP level of some patients also occurs obviously increasing phenomenon.It may be because virus copies propagation in liver cell that hepatopath AFP increases, make the process that liver cell is in damage, repairs and regenerate, and AFP gene is activated in the liver cell of hyperplasia, thus AFP can raise, but concentration is general not too high, how lower than 400ng/mL, and along with the improvement of hepatitis, AFP also declines thereupon, and then recovers normal gradually.At the pregnancy duration of pregnant woman, the change of AFP is also by as an important indicator, under the situation occurring AFP abnormal expression, there will be spina bifida, anencephalus, neural-tube defect (deformity), 21-patau syndrome, even the phenomenon such as dead occurs in fetus uterine cavity.In the patient of teratoma, embryoma, AFP expression also can obviously rise.
Summary of the invention
The object of the invention is to be difficult to solve human body alpha-fetoprotein (AFP) content in prior art the defect determined, providing a kind of whole blood single stage method alpha-fetoprotein gold-immunochromatographyreagent reagent for assay box and detection method thereof to solve the problems referred to above.
To achieve these goals, technical scheme of the present invention is as follows:
A kind of whole blood single stage method alpha-fetoprotein gold-immunochromatographyreagent reagent for assay box, comprise cassette holder, lid and reagent strip, described reagent strip is fixed between described cassette holder and described lid, described lid is provided with viewport, avris between lid and cassette holder is provided with well, can be used for direct finger tip and gets blood or application of sample detection.Described reagent strip is divided into upper strata and bottom, and bottom is plastic sheeting, and upper strata successively headtotail is arranged with glass fibre membrane, nitrocellulose filter one, plastic protective film for plastics, nitrocellulose filter two.Described glass fibre membrane is provided with rabbit igg collaurum, and described nitrocellulose filter one is for being provided with the bridge joint film of AFP collaurum, and described nitrocellulose filter two is provided with AFP monoclonal antibody, goat anti-rabbit igg.
Preferably, use procedure is A, the reagent card of original packing and the blood sample that need detect is equilibrated to room temperature; Take out reagent card from original packing aluminium foil bag before B, use, horizontal positioned, adds sample from adding mouth, and to sample arrival stops ledger line, general application of sample amount is between 35 ~ 40 μ L; Observations in 15 minutes to 30 minutes after C, application of sample;
There is a red stripes as each on the detection line and nature controlling line position of reagent card, illustrate that alpha-fetoprotein colloid is abnormal; As a red stripes appears in the nature controlling line position of only reagent card, illustrate that alpha-fetoprotein colloid is normal; As all there is not red stripes on the detection line and nature controlling line position of reagent card, or only having that a red stripes appears in detection line and band does not appear in nature controlling line, illustrating that testing result is invalid, need resurvey.
Preferably, described detection line and nature controlling line all on nitrocellulose membrane two, between distance be 5.3mm, and the line of alpha-fetoprotein colloid detection line is near application of sample end.
Preferably, described alpha-fetoprotein collaurum line is on nitrocellulose membrane one, and distance alpha-fetoprotein colloid detection line distance is 5mm.Described rabbit igg collaurum line is on glass fibre membrane, and distance alpha-fetoprotein colloid gold thread is 3.5mm.Preferably, the observation panel on described lid runs through lid, is square aperture, and has diaphragm to be affixed on top.
Preferably, the blood capillary pipe seam well between lid and cassette holder both can get blood for finger tip, also may be used for pipettor application of sample.Lid and cassette holder are provided with corresponding engaging or the parts that are fastened and connected, and fasten through described link or fasten.
Compared with prior art, beneficial effect of the present invention is: can human body alpha-fetoprotein (AFP) content and concentration fast and accurately, makes diagnosis in time to disease.
Accompanying drawing explanation
Fig. 1 is the structural front view detecting reagent card
Fig. 2 is the reagent strip structural front view included in reagent card
Fig. 3 is loading methods schematic diagram
Fig. 4 is that result judges schematic diagram
Wherein: 1, outer box, 2, test strips, 3, glass fibre membrane, 4, nitrocellulose filter one, 5, detection line, 6, nature controlling line, 7, nitrocellulose filter two, 8, adding mouth, 9, stop ledger line, 10, result display window.
Embodiment
For making to have a better understanding and awareness architectural feature of the present invention and effect of reaching, coordinating detailed description in order to preferred embodiment and accompanying drawing, being described as follows:
Detect human serum or whole blood sample, method of operating following (see accompanying drawing 3):
(1) reagent card of original packing and the blood sample that need detect are equilibrated to room temperature.
(2) reagent card is taken out from original packing aluminium foil bag before using, horizontal positioned.Added from adding mouth by sample, to sample arrival stops ledger line, general application of sample amount is between 35 ~ 40 μ L.
(3) observations in 15 minutes to 30 minutes after application of sample.
Result explains (see accompanying drawing 4):
There is a red stripes as each on the detection line (T line) and nature controlling line (C line) position of reagent card, AFP abnormal (concentration is not less than 20ng/mL) is described; As a red stripes appears in nature controlling line (C line) position of only reagent card, illustrates that AFP normally (concentration is lower than 20ng/mL); As all there is not red stripes on the detection line (T line) and nature controlling line (C line) position of reagent card, or only have that a red stripes appears in detection line (T line) and band does not appear in nature controlling line (C line), explanation testing result is invalid, need resurvey.
More than show and describe ultimate principle of the present invention, principal character and advantage of the present invention.The technician of the industry should understand; the present invention is not restricted to the described embodiments; the just principle of the present invention described in above-described embodiment and instructions; the present invention also has various changes and modifications without departing from the spirit and scope of the present invention, and these changes and improvements all fall in claimed scope of the present invention.The protection domain of application claims is defined by appending claims and equivalent thereof.
Claims (6)
1. a whole blood single stage method alpha-fetoprotein gold-immunochromatographyreagent reagent for assay box, it is characterized in that: comprise cassette holder, lid and reagent strip, described reagent strip is fixed between described cassette holder and described lid, described lid is provided with viewport, avris between lid and cassette holder is provided with well, can be used for direct finger tip and gets blood or application of sample detection.Described reagent strip is divided into upper strata and bottom, and bottom is plastic sheeting, and upper strata successively headtotail is arranged with glass fibre membrane, nitrocellulose filter one, plastic protective film for plastics, nitrocellulose filter two.Described glass fibre membrane is provided with rabbit igg collaurum, and described nitrocellulose filter one is for being provided with the bridge joint film of AFP collaurum, and described nitrocellulose filter two is provided with AFP monoclonal antibody, goat anti-rabbit igg.
2. the detection method of kit according to claim 1, is characterized in that: described detection method comprises the following steps:
A, the reagent card of original packing and the blood sample that need detect are equilibrated to room temperature;
Take out reagent card from original packing aluminium foil bag before B, use, horizontal positioned, adds sample from adding mouth, and to sample arrival stops ledger line, general application of sample amount is between 35 ~ 40 μ L;
Observations in 15 minutes to 30 minutes after C, application of sample;
There is a red stripes as each on the detection line and nature controlling line position of reagent card, illustrate that alpha-fetoprotein colloid is abnormal; As a red stripes appears in the nature controlling line position of only reagent card, illustrate that alpha-fetoprotein colloid is normal; As all there is not red stripes on the detection line and nature controlling line position of reagent card, or only having that a red stripes appears in detection line and band does not appear in nature controlling line, illustrating that testing result is invalid, need resurvey.
3. the detection method of kit according to claim 2, is characterized in that: described detection line and nature controlling line all on nitrocellulose membrane two, between distance be 5.3mm, and the line of alpha-fetoprotein colloid detection line is near application of sample end.
4. the detection method of kit according to claim 2, is characterized in that: described alpha-fetoprotein collaurum line is on nitrocellulose membrane one, and distance alpha-fetoprotein colloid detection line distance is 5mm.Described rabbit igg collaurum line is on glass fibre membrane, and distance alpha-fetoprotein colloid gold thread is 3.5mm.
5. the detection method of kit according to claim 1, is characterized in that: the observation panel on described lid runs through lid, is square aperture, and has diaphragm to be affixed on top.
6. the detection method of kit according to claim 1, is characterized in that: the blood capillary pipe seam well between lid and cassette holder both can get blood for finger tip, also may be used for pipettor application of sample.Lid and cassette holder are provided with corresponding engaging or the parts that are fastened and connected, and fasten through described link or fasten.
Priority Applications (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201510708316.0A CN105403709A (en) | 2015-10-27 | 2015-10-27 | Whole-blood one-step alpha fetoprotein collaurum detection kit and detection method thereof |
| PCT/CN2015/099833 WO2017071092A1 (en) | 2015-10-27 | 2015-12-30 | Whole blood one-step alpha-fetoprotein colloidal gold detection kit and detection method thereof |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201510708316.0A CN105403709A (en) | 2015-10-27 | 2015-10-27 | Whole-blood one-step alpha fetoprotein collaurum detection kit and detection method thereof |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN105403709A true CN105403709A (en) | 2016-03-16 |
Family
ID=55469318
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201510708316.0A Pending CN105403709A (en) | 2015-10-27 | 2015-10-27 | Whole-blood one-step alpha fetoprotein collaurum detection kit and detection method thereof |
Country Status (2)
| Country | Link |
|---|---|
| CN (1) | CN105403709A (en) |
| WO (1) | WO2017071092A1 (en) |
Families Citing this family (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN111650384A (en) * | 2020-06-22 | 2020-09-11 | 江苏奥雅生物科技有限公司 | Soluble growth stimulation expression gene 2 protein determination kit |
| CN114560936B (en) * | 2022-04-08 | 2022-06-28 | 北京科跃中楷生物技术有限公司 | Fluorescent microsphere labeling method and detection kit |
Citations (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN2501049Y (en) * | 2001-03-13 | 2002-07-17 | 天津三达生物医学工程有限公司 | Three line quick pick-up plate for (HIV) 1-2 type antibody |
| CN1746675A (en) * | 2004-09-07 | 2006-03-15 | 李人 | Immune chromatograph testing strip and production thereof |
| WO2008016271A1 (en) * | 2006-08-02 | 2008-02-07 | Jae Chern Yoo | Thin film chemical analysis apparatus and analysis method using the same |
| CN202471726U (en) * | 2012-02-24 | 2012-10-03 | 上海凯创生物技术有限公司 | Assay kit for alpha fetal protein colloidal gold |
| CN203101402U (en) * | 2013-01-22 | 2013-07-31 | 济南卓冠生物技术有限公司 | Kit for quickly and quantitatively detecting alpha fetoprotein (AFP) by immunochromatography |
| CN104198731A (en) * | 2014-08-28 | 2014-12-10 | 宁波瑞源生物科技有限公司 | C-reactive protein (CRP) semi-quantitative detection reagent and test paper using reagent |
| CN204188626U (en) * | 2014-11-12 | 2015-03-04 | 正元盛邦(天津)生物科技有限公司 | A kind of B-typeNatriuretic Peptide immunochromatography half-quantitative detection test paper |
| CN104459161A (en) * | 2014-12-30 | 2015-03-25 | 霍普金斯医药研究院（北京）有限责任公司 | Alpha fetoprotein colloidal gold test kit and application method thereof |
Family Cites Families (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN104215757B (en) * | 2010-05-28 | 2018-12-04 | 李金波 | Biological fluid sample quantitative test device and its detection method |
-
2015
- 2015-10-27 CN CN201510708316.0A patent/CN105403709A/en active Pending
- 2015-12-30 WO PCT/CN2015/099833 patent/WO2017071092A1/en active Application Filing
Patent Citations (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN2501049Y (en) * | 2001-03-13 | 2002-07-17 | 天津三达生物医学工程有限公司 | Three line quick pick-up plate for (HIV) 1-2 type antibody |
| CN1746675A (en) * | 2004-09-07 | 2006-03-15 | 李人 | Immune chromatograph testing strip and production thereof |
| WO2008016271A1 (en) * | 2006-08-02 | 2008-02-07 | Jae Chern Yoo | Thin film chemical analysis apparatus and analysis method using the same |
| CN202471726U (en) * | 2012-02-24 | 2012-10-03 | 上海凯创生物技术有限公司 | Assay kit for alpha fetal protein colloidal gold |
| CN203101402U (en) * | 2013-01-22 | 2013-07-31 | 济南卓冠生物技术有限公司 | Kit for quickly and quantitatively detecting alpha fetoprotein (AFP) by immunochromatography |
| CN104198731A (en) * | 2014-08-28 | 2014-12-10 | 宁波瑞源生物科技有限公司 | C-reactive protein (CRP) semi-quantitative detection reagent and test paper using reagent |
| CN204188626U (en) * | 2014-11-12 | 2015-03-04 | 正元盛邦(天津)生物科技有限公司 | A kind of B-typeNatriuretic Peptide immunochromatography half-quantitative detection test paper |
| CN104459161A (en) * | 2014-12-30 | 2015-03-25 | 霍普金斯医药研究院（北京）有限责任公司 | Alpha fetoprotein colloidal gold test kit and application method thereof |
Non-Patent Citations (2)
| Title |
|---|
| WANG,CY等: "Simultaneous quantitative detection of multiple tumor markers with a rapid and sensitive multicolor quantum dots based immunochromatographic test strip", 《BIOSENSORS & BIOELECTRONICS》 * |
| 张玉梅等: "全血快速检测甲胎蛋白胶体金免疫层析方法的研制和应用", 《郑州大学学报(医学版) 》 * |
Also Published As
| Publication number | Publication date |
|---|---|
| WO2017071092A1 (en) | 2017-05-04 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| AU2009316392B2 (en) | Method for determining the risk of preeclampsia using PIGF-2 and PIGF-3 markers | |
| CN101871943B (en) | Premature rupture of membrane fast examination tool using ICAM-1 as examination index and examination kit | |
| US20100129935A1 (en) | Pregnancy testing method | |
| Adigun et al. | Alpha fetoprotein | |
| Agarwal et al. | Gestational diabetes screening: the low-cost algorithm | |
| Patil et al. | Inherited and acquired thrombophilia in Indian women experiencing unexplained recurrent pregnancy loss | |
| Halimeh et al. | PBAC score: an easy-to-use tool to predict coagulation disorders in women with idiopathic heavy menstrual bleeding | |
| Kim et al. | Aberrant sialylation and fucosylation of intracellular proteins in cervical tissue are critical markers of cervical carcinogenesis | |
| CN101576495B (en) | Method for detecting N-glycome log (P9/P4) in serum and detecting system and application thereof | |
| CN105403709A (en) | Whole-blood one-step alpha fetoprotein collaurum detection kit and detection method thereof | |
| Adigun et al. | Alpha-fetoprotein analysis | |
| Belirteçleri et al. | Liver function tests as probable markers of preeclampsia—a prospective study conducted in Riyadh | |
| Farias et al. | Flow cytometry in detection of fetal red blood cells and maternal F cells to identify fetomaternal hemorrhage | |
| CN101738474B (en) | Combined test reagent card for cytomegalovirus and rubella virus | |
| US9547899B1 (en) | Mobile hemolysis detection in whole blood samples | |
| CN106198983A (en) | Test kit for ovarian cancer detection | |
| Shamoon et al. | Prevalence and etiological classification of thrombocytopenia among a group of pregnant women in Erbil City, Iraq | |
| CN201697921U (en) | Quick detection tool and detection kit for premature rupture of membrane by taking ICAM-1 as detection index | |
| Fernandes et al. | Flow cytometric assessment of feto‐maternal hemorrhage; a comparison with Betke–Kleihauer | |
| JP6292564B2 (en) | Method, apparatus, computer program product and kit for assisting in predicting recurrence risk of patients with hepatocellular carcinoma | |
| CN211426520U (en) | Combined measles and rubella detection card | |
| Reddy et al. | Clinical and diagnostic features of dengue haemorrhagic fever in children | |
| CN202471726U (en) | Assay kit for alpha fetal protein colloidal gold | |
| RU2775215C1 (en) | Method for early prediction of the development of congenital infectious disease of newborns | |
| CN103852583A (en) | Colloidal gold reagent strip and method for rapidly detecting Boule protein |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| RJ01 | Rejection of invention patent application after publication | ||
| RJ01 | Rejection of invention patent application after publication |
Application publication date: 20160316 |